[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626082":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Pharmicell Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Cellgram-ED Safety Follow-up Group",null,"Participants in this arm previously received Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) via intracavernous injection in the parent phase II clinical trial. This safety follow-up study monitors these participants for long-term safety outcomes for up to 4 years (±30 days) from the completion of the parent trial, including assessment of adverse events and other clinically relevant safety parameters.",[13],{"name":14,"affiliation":15,"role":16},"Bumjin Lim, Ph.D","AIDS Malignancy Consortium","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"daeun jung","CONTACT","82-2-3496-0134","daeun4100@pharmicell.com",[24,40,50,60],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Asan medical center","RECRUITING","Seoul","South Korea",{"type":30,"coordinates":31},"Point",[32,33],126.9784,37.566,{"lat":33,"lon":32},[36],{"name":37,"role":20,"phone":38,"phoneExt":10,"email":39},"Bumjin Im","82-2-3010-1835","lbj1986@hanmail.net",{"facility":41,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":42,"geoPoint":44,"contacts":45},"Ewha womans university medical center",{"type":30,"coordinates":43},[32,33],{"lat":33,"lon":32},[46],{"name":47,"role":20,"phone":48,"phoneExt":10,"email":49},"Kim Chungsu","82-10-2297-3734","cskim37345806@gmail.com",{"facility":51,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"Samsung medical center",{"type":30,"coordinates":53},[32,33],{"lat":33,"lon":32},[56],{"name":57,"role":20,"phone":58,"phoneExt":10,"email":59},"Deokhyun Han","82-2-3410-6431","deokhyun.han@gmail.com",{"facility":61,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":10,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"Seoul ST. Mary's hospital",{"type":30,"coordinates":63},[32,33],{"lat":33,"lon":32},[66],{"name":67,"role":20,"phone":68,"phoneExt":10,"email":69},"Jiyoul Lee","82-2-2258-6227","uroljy@catholic.ac.kr",{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100626082","safety-follow-up-study-of-cellgram-ed-in-post-radical-prostatectomy-erectile-dysfunction-100626082",false,"NCT07431008","Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction","A Safety Follow-up Study of a Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cells) in Patients With Post-Radical Prostatectomy Erectile Dysfunction","Cellgram-ED","Inclusion Criteria:\n\n* Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED).\n* Participants who have provided written informed consent to participate in this safety follow-up study.\n\nExclusion Criteria:","MALE","19 Years","80 Years",{"count":84,"type":85},32,"ESTIMATED","OBSERVATIONAL","This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.",[89],"Erectile Dysfunction","2026-02-20",{"date":92,"type":93},"2026-02-24","ACTUAL",{"date":95,"type":93},"2024-12-26",{"date":97,"type":85},"2030-01-10",{"name":5,"class":6},4]